Cachexia and Wasting Syndrome in Cancer and Chronic Diseases
May 05–07, 2024 | Buck Institute for Research on Aging, Novato, CA, United States
Scientific Organizers:
Bei B. Zhang and Teresa Zimmers
In Person
May 05–07, 2024 | Buck Institute for Research on Aging, Novato, CA, United States
Scientific Organizers:
Bei B. Zhang and Teresa Zimmers
Available Formats:
Supported by the Directors' Fund
In Person
***Meeting program subject to change.
Available Formats: = In PersonMerchandise Options
Registration Options
Fundraising
Booking Function
Fundraising
Sunday, May 5, 2024
Arrival and Registration
4:00–8:00 PM
Courtyard by Marriott Marin Room
Welcome Mixer
6:00–8:00 PM
Courtyard by Marriott Marin Room
Monday, May 6, 2024
Shuttle to Buck Institute
7:45–8:30 AM
Courtyard by Marriott Front Desk
Breakfast and Registration
8:00–9:00 AM
Atrium
Poster Setup
8:30–9:00 AM
Atrium
Welcome Address from the Organizers
9:00–9:30 AM
Drexler Auditorium
Bei B. Zhang, Novo Nordisk
NovoNordisk
NovoNordisk
Teresa Zimmers, Oregon Health and Science University Knight Cancer Institute
Oregon Health and Science University
Oregon Health and Science University
Poster Viewing
9:00–7:00 PM
Atrium
Defining Cachexia as a Disease within a Disease
9:30–12:15 PM
Drexler Auditorium
* Bette Caan, Kaiser Permanente
Session Chair
Session Chair
* Denis C. Guttridge, Medical University of South Carolina
Session Chair
Session Chair
Vickie Baracos, University of Alberta
Clinical Classification of Cancer Cachexia
Clinical Classification of Cancer Cachexia
Stefan D. Anker, Charité Universitätsmedizin Berlin
Cardiac Dysfunction and Wasting at the Heart of Cachexia
Cardiac Dysfunction and Wasting at the Heart of Cachexia
Mariam Jamal-Hanjani, University College London
Insights Into Lung Cancer-Associated Cachexia From the TRACERx Study
Insights Into Lung Cancer-Associated Cachexia From the TRACERx Study
Laure Bindels, Université Catholique de Louvain
Contribution and Therapeutic Prospects from the Gut Microbiome to Cancer Cachexia
Contribution and Therapeutic Prospects from the Gut Microbiome to Cancer Cachexia
Coffee Break
10:30–10:50 AM
Atrium
Lunch
12:15–1:15 PM
Atrium
Poster Session 1
1:00–3:00 PM
Atrium
Coffee Available
3:00–3:30 PM
Atrium
Delineating Underlying Biological Pathways
3:30–5:30 PM
Drexler Auditorium
* David J. Glass, Regeneron Pharmaceuticals, Inc.
Session Chair
Session Chair
* Mariam Jamal-Hanjani, University College London
Session Chair
Session Chair
Teresa Zimmers, Oregon Health and Science University Knight Cancer Institute
Organ Crosstalk in Cachexia
Organ Crosstalk in Cachexia
Tony Tony Hui, Harvard T.H. Chan School of Public Health
Energy Metabolism in Cachexia - Quantitative Fluxomics
Energy Metabolism in Cachexia - Quantitative Fluxomics
Denis C. Guttridge, Medical University of South Carolina
Muscle Microenvironment in Cancer Cachexia
Muscle Microenvironment in Cancer Cachexia
Andrea Graziani, Università di Torino
Short Talk: Short Talk: Impaired cAMP/CREB1 Signaling Drives Mitochondrial Dysfunction in Skeletal Muscle During Cancer Cachexia
Short Talk: Short Talk: Impaired cAMP/CREB1 Signaling Drives Mitochondrial Dysfunction in Skeletal Muscle During Cancer Cachexia
Maria Rohm, Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt
Short Talk: Short Talk: Cancer Cachexia Causes Impaired CD8+ T Cell Activation and Lymphopenia that Contributes to Tissue Wasting
Short Talk: Short Talk: Cancer Cachexia Causes Impaired CD8+ T Cell Activation and Lymphopenia that Contributes to Tissue Wasting
Introduction of the Cancer Cachexia Society
5:30–5:35 PM
Drexler Auditorium
Andrea Bonetto, University of Colorado Anschutz Medical Campus
On Own for Dinner
5:35–8:00 PM
Dessert Social Hour with Trivia
8:00–9:00 PM
Courtyard by Marriott Marin Room
Tuesday, May 7, 2024
Shuttle to Buck Institute
7:45–8:30 AM
Courtyard by Marriott Front Desk
Breakfast
8:00–9:00 AM
Atrium
Poster Setup
8:30–9:00 AM
Atrium
Cachexia in Chronic Illness
9:00–12:00 PM
Drexler Auditorium
* Danna M. Breen, Pfizer Inc.
Session Chair
Session Chair
* Laure Bindels, Université Catholique de Louvain
Session Chair
Session Chair
Marcus D. Goncalves, Weill Cornell Medicine
Cachexia and Cancer
Cachexia and Cancer
Philip A. Efron, University of Florida
Persistent Inflammatory/Immunosuppressive Catabolic Syndrome (PICS) after Sepsis
Persistent Inflammatory/Immunosuppressive Catabolic Syndrome (PICS) after Sepsis
David J. Glass, Regeneron Pharmaceuticals, Inc.
Cachexia and COVID-19
Cachexia and COVID-19
Marilia C Seelaender, University of São Paulo
Adipose Tissue Role in Acute COVID-19 and Long COVID Syndrome: A New Form of Cachexia?
Adipose Tissue Role in Acute COVID-19 and Long COVID Syndrome: A New Form of Cachexia?
Shinpei Kawaoka, Tohoku University / Kyoto university
Short Talk: Short Talk: Systemic Metabolic and Immune Defects in Advanced Cancer Patients Prior to the Onset of Pre-Cachexia
Short Talk: Short Talk: Systemic Metabolic and Immune Defects in Advanced Cancer Patients Prior to the Onset of Pre-Cachexia
Aliesha Garrett, Terasaki Institute for Biomedical Innovation
Short Talk: Short Talk: Vagal Perturbation of the Liver-Brain Axis Deters Cancer-Associated Cachexia Independent of Tumor Burden
Short Talk: Short Talk: Vagal Perturbation of the Liver-Brain Axis Deters Cancer-Associated Cachexia Independent of Tumor Burden
Poster Viewing
9:00–7:00 PM
Atrium
Coffee Break
10:00–10:20 AM
Atrium
Lunch
12:00–1:00 PM
Atrium
Poster Session 2
12:30–2:30 PM
Atrium
Workshop
2:30–4:30 PM
Drexler Auditorium
* Tony Tony Hui, Harvard T.H. Chan School of Public Health
Session Chair
Session Chair
* Rodney Infante, University of Texas Southwestern Medical School
Session Chair
Session Chair
Houda Cohen, University of Minnesota
Chronic Cardiac Wasting-Associated Cardiomyopathy in Post-Tumor-Mediated Cancer Cachexia
Chronic Cardiac Wasting-Associated Cardiomyopathy in Post-Tumor-Mediated Cancer Cachexia
Anja Karlstaedt, Cedars Sinai Medical Center
D2-HG Promotes IDH-Mutant Cancer-Associated Autophagic Proteolysis Skeletal Muscle
D2-HG Promotes IDH-Mutant Cancer-Associated Autophagic Proteolysis Skeletal Muscle
Hassan Fakih, UMass Chan Medical School
Efficacious and Durable Myostatin Knockdown Using Chemically Optimized siRNAs
Efficacious and Durable Myostatin Knockdown Using Chemically Optimized siRNAs
Hong-Wen Tang, Duke-NUS Medical School
Deaf1 Regulates Muscle Regeneration through Autophagy
Deaf1 Regulates Muscle Regeneration through Autophagy
Muhannad Abu-Remaileh, Dana Farber Cancer Institute
Roles of HIF2 and PTHLH in Kidney Cancer-Associated Cachexia: Treatment with a First-In-Class Agent
Roles of HIF2 and PTHLH in Kidney Cancer-Associated Cachexia: Treatment with a First-In-Class Agent
Venise Jan Castillon, Memorial Sloan Kettering Cancer Center
Systemic Physiological Changes Indicative of Cancer Cachexia at Diagnosis
Systemic Physiological Changes Indicative of Cancer Cachexia at Diagnosis
Justin L Shahtout, University of Utah
Targeting Skeletal Muscle Lipid Hydroperoxides in Cancer Cachexia
Targeting Skeletal Muscle Lipid Hydroperoxides in Cancer Cachexia
Paige Arneson-Wissink, OHSU
PDAC Recovery Associates with Impaired Hepatic metabolism, Delayed Muscle Recovery, and Decreased Activity Levels
PDAC Recovery Associates with Impaired Hepatic metabolism, Delayed Muscle Recovery, and Decreased Activity Levels
Coffee Available
4:30–5:00 PM
Atrium
Approaches to Therapeutic Intervention
5:00–7:00 PM
Drexler Auditorium
* Marcus D. Goncalves, Weill Cornell Medicine
Session Chair
Session Chair
* Vickie Baracos, University of Alberta
Session Chair
Session Chair
Steven Heymsfield, Pennington Biomedical Research Center
Digital Technology for Body Weight Phenotyping
Digital Technology for Body Weight Phenotyping
Rodney Infante, University of Texas Southwestern Medical School
Harnessing Cachexia Mechanisms to Elucidate Tumor-directed Therapies
Harnessing Cachexia Mechanisms to Elucidate Tumor-directed Therapies
Danna M. Breen, Pfizer Inc.
GDF15/Ponsegromab: A Potential Treatment for Cachexia
GDF15/Ponsegromab: A Potential Treatment for Cachexia
Kate Orlowsky, AVEO Oncology
Short Talk: Short Talk: A Phase 1b Dose Escalation Study of AV-380 in Combination with Standard of Care Chemotherapy in Metastatic Cancer Patients (pts) with Cachexia and Elevated GDF-15 Levels
Short Talk: Short Talk: A Phase 1b Dose Escalation Study of AV-380 in Combination with Standard of Care Chemotherapy in Metastatic Cancer Patients (pts) with Cachexia and Elevated GDF-15 Levels
Andrei Turtoi, INSERM Cancer Research Institute of Montpellier, France
Short Talk: Short Talk: Nozomitumab: A Potential Treatment for Prevention of Cancer-Induced Cachexia via Reprogramming Macrophage Function in Adipose and Muscle Tissues
Short Talk: Short Talk: Nozomitumab: A Potential Treatment for Prevention of Cancer-Induced Cachexia via Reprogramming Macrophage Function in Adipose and Muscle Tissues
On Own for Dinner
7:00–8:00 PM
Transportation to Novato for Dinner
7:45–9:30 PM
Courtyard by Marriott Front Desk
Subscribe for Updates